Keywords: can-fite, initiates, ph, i/ii, trial, liver, cancer

Can-Fite initiates Ph I/II trial of liver cancer drug

Article | 20 April 2009

Print This

Can-Fite BioPharma, an Israeli biotechnology company, says that a Phase I/II trial with CF102 for the treatment of liver ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in